Re­gen­eron earns mid-stage win for high­er dose of Eylea, hop­ing to re­fresh its sales pitch

Re­gen­eron has made its name on the block­buster suc­cess of eye drug Eylea, but with the ag­ing drug fac­ing a raft of com­peti­tors the drug­mak­er is look­ing for ways to keep its sales pitch fresh. And re­searchers are blaz­ing a fresh trail on that front with new mid-stage da­ta out to­day.

Forty-three per­cent of wet age-re­lat­ed mac­u­lar de­gen­er­a­tion pa­tients dosed with an 8 mg dose of Eylea re­port­ed no reti­nal flu­id af­ter four weeks com­pared with 26.4% of pa­tients re­ceiv­ing a 2 mg dose of the drug, ac­cord­ing to topline da­ta from a Phase II study un­veiled Tues­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.